Saeed Dabestani

Medicine and Dentistry

1. Clear Cell Renal Cell Carcinoma 100%
2. Patient 78%
3. Urology 63%
4. Association 54%
5. Systematic Review 53%
6. Therapeutic Procedure 44%
7. Follow up 18%
8. Surgery 17%
9. Nivolumab 15%
10. Metastatic Carcinoma 14%
11. Clear Cell 13%
12. Combination Therapy 12%
13. Overall Survival 12%
14. Meta-Analysis 11%
15. Biological Marker 11%
16. Immune Checkpoint Inhibitor 11%
17. Kidney Tumour 9%
18. Partial Nephrectomy 9%
19. Cohort Analysis 8%
20. Cabozantinib 8%
21. Nephrectomy 8%
22. Metastasectomy 8%
23. Sunitinib 7%
24. Thromboprophylaxis 7%
25. Prostate Cancer 7%
26. Glycosaminoglycan 7%
27. Disease 7%
28. Randomized Controlled Trial 7%
29. Adjuvant Therapy 6%
30. Hazard Ratio 6%
31. Kidney Metastasis 6%
32. Systemic Therapy 5%
33. Axitinib 5%
34. Adverse Event 5%
35. Radical Nephrectomy 5%
36. Pain 5%